和黄医药：沃瑞沙ORPATHYS获中国大陆附条件批准
2026-07-02 10:33:21
和黄医药（中国）（0013）宣布，沃瑞沙（ORPATHYS，赛沃替尼/savolitinib）的新药上市申请获中国国家药品监督管理局附条件批准，据明报报道，用于治疗经至少2种系统治疗后失败、MET基因扩增的局部晚期或转移性胃癌或胃食管结合部（GC/GEJ）腺癌成人患者。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
STOCKS | Hutchmed (China) Says ORPATHYS Approved in China for MET-Amplified GC/GEJ CancerNext article：
股票市场 | 富国银行调整Meta等三股目标价
